---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Expected outcomes of therapy"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Expected outcomes of therapy. Topics: Positive airway pressure: sleepiness, sleep-related quality of life, and blood pressure; Positive airway pressure: motor vehicle crash risk; Treatment targets for residual AHI in the VA/DoD 2025 guideline; Effectiveness accounting for adherence: mean disease alleviation; 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Positive airway pressure: sleepiness, sleep-related quality of life, and blood pressure

> “Meta-analyses demonstrated a clinically significant improvement in sleepiness with the use of PAP to treat adults with OSA as compared with no treatment. The overall quality of evidence, based on the critical outcome of sleepiness, was high.”
> “Meta-analyses of sleep-related QOL, as assessed by the Calgary Sleep Apnea QOL Index (SAQLI) and the Functional Outcomes of Sleep Questionnaire (FOSQ), demonstrated a clinically significant improvement. However, meta-analyses of global QOL, as assessed by the SF-36 component scores, demonstrated no clinically significant improvement.”
> “Meta-analyses demonstrated clinically significant BP reductions in nocturnal, daytime, and 24-hour systolic and diastolic BP when all patients in the studies were considered, with the largest effects seen for nocturnal measurements.”

Source: [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/)

<a id="topic-2.2.2.7-2"></a>

### Positive airway pressure: motor vehicle crash risk

> “A meta-analysis of 9 observational studies examining crash risk of drivers with OSA pre- vs. post-CPAP found a significant risk reduction following treatment (risk ratio = 0.278, 95% CI: 0.22 to 0.35; P < 0.001).”

Source: [Tregear et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2941424/)

<a id="topic-2.2.2.7-3"></a>

### Treatment targets for residual AHI in the VA/DoD 2025 guideline

> “For PAP therapy, this includes an automated interrogation of the device to ensure that the residual AHI is less than 5 events/hr.”
> “For patients with very severe OSA, it may not be feasible to reduce the AHI to less than 5 and in these cases, consultation with a sleep specialist is recommended.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.7-4"></a>

### Effectiveness accounting for adherence: mean disease alleviation

> “Mean disease alleviation is a metric that incorporates adherence and efficacy to estimate real-world effectiveness [11]. Therefore, comparisons among treatments should be based on effectiveness rather than efficacy alone.”
> “Given the low adherence rates associated with PAP, a treatment that reduces the AHI to below 10 events/h, or even to a higher residual AHI, could achieve effectiveness similar to that of PAP with a residual AHI below 5 events/h if adherence is substantially better.”

Source: [Kim (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13434379/)

> “Studies should incorporate mean disease alleviation, a metric that incorporates both treatment efficacy and hours of therapy use as outcomes.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.7-5"></a>

### Outcome metrics beyond AHI

> “Development of this Research Statement was motivated by a growing recognition of the limitations of the AHI to predict adverse effects of OSA and to predict responsiveness to treatment.”

Source: [Malhotra et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8271129/)

<a id="topic-2.2.2.7-6"></a>

### AD109: magnitude of AHI change and categorical outcomes in SynAIRgy, AHI with 4% desaturation hypopnea rule, treatment policy estimand

> “Among 646 participants (median apnea-hypopnea index [AHI], 19.6), treatment with AD109 over 26 weeks resulted in a placebo-adjusted reduction in AHI of approximately 4 events per hour. The clinical significance of this magnitude of reduction is uncertain when considered as a continuous measure.”
> “However, categorical analyses provide additional context: 41.8% of participants receiving AD109, as compared with 33.6% receiving placebo, had a decrease in AHI sufficient to shift to a lower severity category, and 17.6% achieved an AHI of less than 5 events per hour, compared with 9.3% in the placebo group.”
> “Whether pharmacologic reductions in hypoxic burden translate into improved clinical outcomes remains uncertain, but the observed changes are consistent with a biologically plausible mechanism of benefit.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

<a id="topic-2.2.2.7-7"></a>

### AD109: baseline severity and absolute effect size, authors' interpretation of SynAIRgy

> “The population studied skewed toward mild-to-moderate baseline disease severity, which can contribute to limited absolute effects despite meaningful proportional improvements.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.2.2.7-8"></a>

### AD109: outcomes not yet established

> “The durability of the observed physiologic effects beyond 26 weeks (with results forthcoming from the 51-week LUNAIRO trial), the long-term safety profile of combined noradrenergic and antimuscarinic therapy, and the impact on clinically meaningful outcomes, including cardiovascular events, require further study.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
